scholarly journals Photoactivatable dihydroalkaloids for cancer theranostics with AIE characteristics

2020 ◽  
Author(s):  
Xia Ling ◽  
Letao Huang ◽  
Youzhen Li ◽  
Qing Wan ◽  
Zhiming Wang ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Cancer Cells ◽  
Treatment Efficacy ◽  
Therapeutic Dose ◽  
Dehydrogenation Reaction ◽  
Precise Control ◽  
Image Guided ◽  
New Strategy ◽  
Cancer Theranostics

Chemotherapeutics with systemic administration usually suffer from low treatment efficacy and off-target toxicity. In contrary, the photoactivatable cancer theranostics can achieve image-guided precise control of therapeutic dose and location. However, the conventional photoactivatable chemotherapeutics usually require decoration of chemotherapeutics with additional photo-responsive groups through tedious synthetic procedures, which can lead to undesirable toxic byproducts and seriously restrict their applications. Herein, we propose a new strategy for photoactivatable caner theranostics based on photooxidative dehydrogenation reaction, which is only associating with water as the byproduct. To demonstrate the power of this strategy, we utilized the natural dihydrobenzo[c]phenanthridine alkaloids of DHCHE and DHSAN as photoactivatable theranostics to achieve selective imaging and killing of cancer cells by in situ transformation into nucleus-targeted CHE and SAN under light irradiation. Notably, CHE is featured with aggregation-induced emission (AIE) characteristics, which can be used for precise control of the photoactivatable therapeutic dose. This photoactivatable strategy based on dihydroalkaloids is thus promising for precise cancer treatment in clinic.<br>

scholarly journals Photoactivatable dihydroalkaloids for cancer theranostics with AIE characteristics

2020 ◽  
Author(s):  
Xia Ling ◽  
Letao Huang ◽  
Youzhen Li ◽  
Qing Wan ◽  
Zhiming Wang ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Cancer Cells ◽  
Treatment Efficacy ◽  
Therapeutic Dose ◽  
Dehydrogenation Reaction ◽  
Precise Control ◽  
Image Guided ◽  
New Strategy ◽  
Cancer Theranostics

Chemotherapeutics with systemic administration usually suffer from low treatment efficacy and off-target toxicity. In contrary, the photoactivatable cancer theranostics can achieve image-guided precise control of therapeutic dose and location. However, the conventional photoactivatable chemotherapeutics usually require decoration of chemotherapeutics with additional photo-responsive groups through tedious synthetic procedures, which can lead to undesirable toxic byproducts and seriously restrict their applications. Herein, we propose a new strategy for photoactivatable caner theranostics based on photooxidative dehydrogenation reaction, which is only associating with water as the byproduct. To demonstrate the power of this strategy, we utilized the natural dihydrobenzo[c]phenanthridine alkaloids of DHCHE and DHSAN as photoactivatable theranostics to achieve selective imaging and killing of cancer cells by in situ transformation into nucleus-targeted CHE and SAN under light irradiation. Notably, CHE is featured with aggregation-induced emission (AIE) characteristics, which can be used for precise control of the photoactivatable therapeutic dose. This photoactivatable strategy based on dihydroalkaloids is thus promising for precise cancer treatment in clinic.<br>

Magnetic Nanoliposomes as in Situ Microbubble Bombers for Multimodality Image-Guided Cancer Theranostics

ACS Nano ◽  
2017 ◽  
Vol 11 (2) ◽  
pp. 1509-1519 ◽  
Author(s):  
Yang Liu ◽  
Fang Yang ◽  
Chuxiao Yuan ◽  
Mingxi Li ◽  
Tuantuan Wang ◽  
...  
Keyword(s):  
Image Guided ◽  
Multimodality Image ◽  
Cancer Theranostics

scholarly journals Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

2021 ◽  
Author(s):  
Xin Yang ◽  
Limin Ma ◽  
Hongwei Shao ◽  
Xia Ling ◽  
Mengyu Yao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Treatment ◽  
Density Functional ◽  
Cancer Drug ◽  
Spatiotemporal Resolution ◽  
Precise Control ◽  
Catalytic Activation ◽  
Anti Cancer

Chemotherapies for cancer treatment usually suffer from poor targeting ability and serious side-effects. To improve the treatment efficiency and reduce side effects, photoactivatable chemotherapy has been recently proposed for precise cancer treatment with high spatiotemporal resolution. However, most photoactivatable prodrugs require decoration by stoichiometric photo-cleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency. To tackle these challenges, we herein propose a bioorthogonal photo-catalytic activation strategy with riboflavin as the catalyst for in situ transformation of prodrug dihydrochelerythrine (DHCHE) prodrug into anti-cancer drug chelerythrine (CHE), which can efficiently kill cancer cells and inhibit in vivo tumor growth under light irradiation. Meanwhile, the photo-catalytic transformation from DHCHE into CHE was in situ monitored by green-to-red fluorescence conversion, which can be used for precise control of the therapeutic dose. The photocatalytic mechanism was also fully explored by means of density functional theory (DFT) calculations. We believe this imaging-guided bioorthogonal photo-catalytic activation strategy is promising for cancer chemotherapy in clinical applications.

scholarly journals Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

2021 ◽  
Author(s):  
Xin Yang ◽  
Limin Ma ◽  
Hongwei Shao ◽  
Xia Ling ◽  
Mengyu Yao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Treatment ◽  
Cancer Drug ◽  
Spatiotemporal Resolution ◽  
Precise Control ◽  
Catalytic Activation ◽  
Anti Cancer ◽  
Targeting Ability

Chemotherapies for cancer treatment usually suffer from poor targeting ability and serious side-effects. To improve the treatment efficiency and reduce side effects, photoactivatable chemotherapy has been recently proposed for precise cancer treatment with high spatiotemporal resolution. However, most photoactivatable prodrugs require decoration by stoichiometric photo-cleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency. To tackle these challenges, we herein propose a bioorthogonal photo-catalytic activation strategy with riboflavin as the catalyst for in situ transformation of prodrug dihydrochelerythrine (DHCHE) prodrug into anti-cancer drug chelerythrine (CHE), which can efficiently kill cancer cells and inhibit in vivo tumor growth under light irradiation. Meanwhile, the photo-catalytic transformation from DHCHE into CHE can be in situ monitored by green-to-red fluorescence conversion, which can be used for precise control of the therapeutic dose. We believe this imaging-guided bioorthogonal photo-catalytic strategy is promising for cancer treatment in clinical applications.

scholarly journals Chemodynamic nanomaterials for cancer theranostics

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Jingqi Xin ◽  
Caiting Deng ◽  
Omer Aras ◽  
Mengjiao Zhou ◽  
Chunsheng Wu ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Combination Therapy ◽  
Cancer Cells ◽  
Hypoxic Condition ◽  
Anticancer Efficacy ◽  
Anticancer Treatment ◽  
The One ◽  
Cancer Theranostics ◽  
New Strategies

AbstractIt is of utmost urgency to achieve effective and safe anticancer treatment with the increasing mortality rate of cancer. Novel anticancer drugs and strategies need to be designed for enhanced therapeutic efficacy. Fenton- and Fenton-like reaction-based chemodynamic therapy (CDT) are new strategies to enhance anticancer efficacy due to their capacity to generate reactive oxygen species (ROS) and oxygen (O2). On the one hand, the generated ROS can damage the cancer cells directly. On the other hand, the generated O2 can relieve the hypoxic condition in the tumor microenvironment (TME) which hinders efficient photodynamic therapy, radiotherapy, etc. Therefore, CDT can be used together with many other therapeutic strategies for synergistically enhanced combination therapy. The antitumor applications of Fenton- and Fenton-like reaction-based nanomaterials will be discussed in this review, including: (iþ) producing abundant ROS in-situ to kill cancer cells directly, (ii) enhancing therapeutic efficiency indirectly by Fenton reaction-mediated combination therapy, (iii) diagnosis and monitoring of cancer therapy. These strategies exhibit the potential of CDT-based nanomaterials for efficient cancer therapy.

scholarly journals BIOPREPARATION FOR IN SITU ANTITUMOR VACCINATION

ASJ. ◽  
2021 ◽  
Vol 2 (45) ◽  
pp. 4-7
Author(s):  
A. Zinchenko ◽  
L. Birichevskaya ◽  
A, Shchokolova ◽  
P. Krasochko ◽  
A. Barashkov
Keyword(s):  
Breast Carcinoma ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Test Model ◽  
Preliminary Results ◽  
Biological Preparation ◽  
Cyclic Diguanosine Monophosphate ◽  
Diguanosine Monophosphate

The present study is focused on the first attempt to use an enzymatically produced biological preparation of cyclic diguanosine monophosphate (cyclic di-GMP) for the therapy of animal cancer. Feline breast carcinoma was chosen as the test model. The preparation was administered intratumorally to induce the immunogenic death of a part of the cancer cells and thus carry out the so-called in situ antitumor vaccination. Preliminary results indicate good therapeutic prospects of studied biopreparation for animal cancer treatment. In conclusion, the expedience of further trials of cyclic di-GMP preparation for in situ antitumor vaccination was stated. The need to supplement this mono-preparation with another immunostimulating adjuvant characterized by a mechanism of action distinct from that exhibited by cyclic di-GMP was emphasized. DNA preparation comprising the so-called immunostimulating CpG motifs was provided as an example of such compound. 

New strategy for precise cancer therapy: tumor-specific delivery of mitochondria-targeting photodynamic therapy agents and in situ O2-generation in hypoxic tumors

2020 ◽  
Vol 8 (14) ◽  
pp. 3994-4002
Author(s):  
Huachao Chen ◽  
Chengkun He ◽  
Tianyi Chen ◽  
Xuling Xue
Keyword(s):  
Photodynamic Therapy ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
New Strategy ◽  
Mitochondria Targeting

This work reports new ROS-responsive and O2-producing nanoparticles to achieve selective and mitochondria-targeted PDT for cancer treatment against hypoxic tumors.

scholarly journals Bioorthogonal Photo-Catalytic Activation of an Anti-Cancer Prodrug by Riboflavin

2021 ◽  
Author(s):  
Xin Yang ◽  
Limin Ma ◽  
Hongwei Shao ◽  
Xia Ling ◽  
Mengyu Yao ◽  
...  
Keyword(s):  
Side Effects ◽  
Cancer Treatment ◽  
Density Functional ◽  
Cancer Drug ◽  
Spatiotemporal Resolution ◽  
Precise Control ◽  
Catalytic Activation ◽  
Anti Cancer

Chemotherapies for cancer treatment usually suffer from poor targeting ability and serious side-effects. To improve the treatment efficiency and reduce side effects, photoactivatable chemotherapy has been recently proposed for precise cancer treatment with high spatiotemporal resolution. However, most photoactivatable prodrugs require decoration by stoichiometric photo-cleavable groups, which are only responsive to ultraviolet irradiation and suffer from low reaction efficiency. To tackle these challenges, we herein propose a bioorthogonal photo-catalytic activation strategy with riboflavin as the catalyst for in situ transformation of prodrug dihydrochelerythrine (DHCHE) prodrug into anti-cancer drug chelerythrine (CHE), which can efficiently kill cancer cells and inhibit in vivo tumor growth under light irradiation. Meanwhile, the photo-catalytic transformation from DHCHE into CHE was in situ monitored by green-to-red fluorescence conversion, which can be used for precise control of the therapeutic dose. The photocatalytic mechanism was also fully explored by means of density functional theory (DFT) calculations. We believe this imaging-guided bioorthogonal photo-catalytic activation strategy is promising for cancer chemotherapy in clinical applications.

Resveratrol as an Adjuvant for Normal Tissues Protection and Tumor Sensitization

2020 ◽  
Vol 20 (2) ◽  
pp. 130-145 ◽  
Author(s):  
Keywan Mortezaee ◽  
Masoud Najafi ◽  
Bagher Farhood ◽  
Amirhossein Ahmadi ◽  
Dheyauldeen Shabeeb ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Clinical Studies ◽  
Normal Tissue ◽  
Medical Science ◽  
Treatment Modalities ◽  
Radiation Toxicity ◽  
Normal Tissues ◽  
Normal Tissue Toxicity

Cancer is one of the most complicated diseases in present-day medical science. Yearly, several studies suggest various strategies for preventing carcinogenesis. Furthermore, experiments for the treatment of cancer with low side effects are ongoing. Chemotherapy, targeted therapy, radiotherapy and immunotherapy are the most common non-invasive strategies for cancer treatment. One of the most challenging issues encountered with these modalities is low effectiveness, as well as normal tissue toxicity for chemo-radiation therapy. The use of some agents as adjuvants has been suggested to improve tumor responses and also alleviate normal tissue toxicity. Resveratrol, a natural flavonoid, has attracted a lot of attention for the management of both tumor and normal tissue responses to various modalities of cancer therapy. As an antioxidant and anti-inflammatory agent, in vitro and in vivo studies show that it is able to mitigate chemo-radiation toxicity in normal tissues. However, clinical studies to confirm the usage of resveratrol as a chemo-radioprotector are lacking. In addition, it can sensitize various types of cancer cells to both chemotherapy drugs and radiation. In recent years, some clinical studies suggested that resveratrol may have an effect on inducing cancer cell killing. Yet, clinical translation of resveratrol has not yielded desirable results for the combination of resveratrol with radiotherapy, targeted therapy or immunotherapy. In this paper, we review the potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities.

Sign in / Sign up

Export Citation Format

Share Document